Mono Pharmacare Ltd
Incorporated in 1994, Mono Pharmacare Ltd is in the business of distribution of Pharmaceutical items[1]
- Market Cap ₹ 40.3 Cr.
- Current Price ₹ 22.8
- High / Low ₹ 42.0 / 22.1
- Stock P/E 13.0
- Book Value ₹ 17.7
- Dividend Yield 0.00 %
- ROCE 11.0 %
- ROE 10.4 %
- Face Value ₹ 10.0
Pros
- Debtor days have improved from 160 to 90.8 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Half Yearly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| 27 | 122 | 168 | |
| 25 | 116 | 161 | |
| Operating Profit | 2 | 6 | 8 |
| OPM % | 6% | 5% | 5% |
| 0 | 0 | 1 | |
| Interest | 1 | 3 | 4 |
| Depreciation | 0 | 0 | 0 |
| Profit before tax | 1 | 3 | 4 |
| Tax % | 25% | 24% | 30% |
| 1 | 2 | 3 | |
| EPS in Rs | 0.57 | 1.38 | 1.75 |
| Dividend Payout % | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 38% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 27% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | -43% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 10% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Equity Capital | 12 | 18 | 18 |
| Reserves | 1 | 10 | 14 |
| 40 | 41 | 54 | |
| 9 | 12 | 25 | |
| Total Liabilities | 63 | 81 | 110 |
| 1 | 1 | 1 | |
| CWIP | 0 | 0 | 0 |
| Investments | 1 | 0 | 0 |
| 61 | 80 | 109 | |
| Total Assets | 63 | 81 | 110 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| -28 | -9 | -4 | |
| -1 | 0 | -0 | |
| 30 | 8 | 5 | |
| Net Cash Flow | 0 | -0 | 0 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|
| Debtor Days | 296 | 94 | 91 |
| Inventory Days | 497 | 139 | 133 |
| Days Payable | 103 | 32 | 45 |
| Cash Conversion Cycle | 689 | 202 | 179 |
| Working Capital Days | 703 | 204 | 180 |
| ROCE % | 10% | 11% |
Documents
Announcements
-
Structural Digital Database
24 July 2025 - Compliance certificate for SEBI insider trading database for FY ended March 31, 2025, no non-compliances.
-
Structural Digital Database
22 July 2025 - Compliance certificate confirming proper maintenance of insider trading digital database for March 2025 quarter.
-
Structural Digital Database
15 July 2025 - Compliance certificate for SEBI insider trading database for quarter ended June 30, 2025.
-
Certificate under SEBI (Depositories and Participants) Regulations, 2018
14 July 2025 - SEBI compliance certificate confirming securities dematerialization for quarter ended June 30, 2025.
-
Structural Digital Database
5 July 2025 - SDD COMPLIANCE CERTIFICATE FOR THE QUARTER ENDED MARCH 31st, 2025
Business Overview:[1]
MPL is a distributor and supplier of a wide array of pharmaceutical products and medicines. It offers
Health Care Products, Antibiotic medicines, Cough Cold Anti-Allergic medicines, Antifungal medicines, Nutraceutical medicines, Analgesic & Antipyretic medicines, Antacid
& Antiemetic medicines, Cardiac – Diabetic medicines, and Cosmo care products.